Y Combinator · Aug 2024
YC publicly congratulated the team, restated the tissue-targeting thesis, and referenced investors including Y Combinator, Ethan Perlstein, and Oleksiy Ignatyev.
Enabling Tissue Targeting of Therapies
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Eugit Therapeutics is a San Carlos biotech developing TAGHOME, a tissue-targeting therapeutic platform that uses engineered gamma delta T cells and T-cell-receptor-based delivery to reduce toxicity and improve precision in inflammatory disease and cancer. Public company materials still list Nizar Batada as CEO/Co-Founder, Yoshinori Fukazawa as VP of Research/Co-Founder, and George Church as Scientific Advisor/Co-Founder, but their personal LinkedIn profiles indicate they have since moved to other roles, so current operating leadership is not fully transparent publicly.
Primary product
TAGHOME tissue-targeting drug-delivery / gamma delta T-cell platform
Founded
2022
Headquarters
San Carlos, California, United States
Team size
1-10 employees
Industry
Biotechnology Research
Sub-industry
Tissue-targeted immunotherapy / cell therapy
Open Positions
0 jobs at Eugit Therapeutics
No open positions
Check back later for new openings